help button home button Endocrine Society Molecular Endocrinology ENDO 08 Sessions Library
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Molecular Endocrinology, doi:10.1210/me.2003-0436
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow NURSA Molecule Pages Link
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Masiello, D.
Right arrow Articles by Balk, S. P.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Masiello, D.
Right arrow Articles by Balk, S. P.
Molecular Endocrinology 18 (10): 2388-2401
Copyright © 2004 by The Endocrine Society

Recruitment of ß-Catenin by Wild-Type or Mutant Androgen Receptors Correlates with Ligand-Stimulated Growth of Prostate Cancer Cells

David Masiello, Shao-Yong Chen, Youyuan Xu, Manon C. Verhoeven, Eunis Choi, Anthony N. Hollenberg and Steven P. Balk

Cancer Biology Program/Hematology-Oncology Division (D.M., S.-Y.C., Y.X., M.C.V., E.C., S.P.B.) and the Thyroid Unit/Endocrinology Division (A.N.H.), Department of Medicine, Beth Israel Deaconess Medical Center and Harvard Medical School, Boston, Massachusetts 02215; and University of Utrecht (M.C.V.), 3508 GA, Utrecht, The Netherlands

Address all correspondence and requests for reprints to: Steven P. Balk, Hematology-Oncology Division, Beth Israel Deaconess Medical Center, 330 Brookline Avenue, Boston, Massachusetts 02215. E-mail: sbalk{at}bidmc.harvard.edu.

Prostate cancers respond to treatments that suppress androgen receptor (AR) function, with bicalutamide, flutamide, and cyproterone acetate (CPA) being AR antagonists in clinical use. As CPA has substantial agonist activity, it was examined to identify AR coactivator/corepressor interactions that may mediate androgen-stimulated prostate cancer growth. The CPA-liganded AR was coactivated by steroid receptor coactivator-1 (SRC-1) but did not mediate N-C terminal interactions or recruit ß-catenin, indicating a nonagonist conformation. Nonetheless, CPA did not enhance AR interaction with nuclear receptor corepressor, whereas the AR antagonist RU486 (mifepristone) strongly stimulated AR-nuclear receptor corepressor binding. The role of coactivators was further assessed with a T877A AR mutation, found in LNCaP prostate cancer cells, which converts hydroxyflutamide (HF, the active flutamide metabolite) into an agonist that stimulates LNCaP cell growth. The HF and CPA-liganded T877A ARs were coactivated by SRC-1, but only the HF-liganded T877A AR was coactivated by ß-catenin. L-39, a novel AR antagonist that transcriptionally activates the T877A AR, but still inhibits LNCaP growth, similarly mediated recruitment of SRC-1 and not ß-catenin. In contrast, ß-catenin coactivated a bicalutamide-responsive mutant AR (W741C) isolated from a bicalutamide-stimulated LNCaP subline, further implicating ß-catenin recruitment in AR-stimulated growth. Androgen-stimulated prostate-specific antigen gene expression in LNCaP cells could be modulated by ß-catenin, and endogenous c-myc expression was repressed by dihydrotestosterone, but not CPA. These results indicate that interactions between AR and ß-catenin contribute to prostate cell growth in vivo, although specific growth promoting genes positively regulated by AR recruitment of ß-catenin remain to be identified.

NURSA Molecule Pages Link:

Nuclear Receptors:   GR  |  PR  |  AR
Coregulators:   SRC-1  |  NCOR
Ligands:   Dihydrotestosterone  |  RU486  |  Bicalutamide



This article has been cited by other articles:


Home page
 Cancer Res.Home page
G. Wang, J. Wang, and M. D. Sadar
Crosstalk between the Androgen Receptor and {beta}-Catenin in Castrate-Resistant Prostate Cancer
Cancer Res., December 1, 2008; 68(23): 9918 - 9927.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. C. Hodgson, H. C. Shen, A. N. Hollenberg, and S. P. Balk
Structural basis for nuclear receptor corepressor recruitment by antagonist-liganded androgen receptor
Mol. Cancer Ther., October 1, 2008; 7(10): 3187 - 3194.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
M. C. Hodgson, I. Astapova, A. N. Hollenberg, and S. P. Balk
Activity of Androgen Receptor Antagonist Bicalutamide in Prostate Cancer Cells Is Independent of NCoR and SMRT Corepressors
Cancer Res., September 1, 2007; 67(17): 8388 - 8395.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
N. Harada, R. Yasunaga, Y. Higashimura, R. Yamaji, K. Fujimoto, J. Moss, H. Inui, and Y. Nakano
Glyceraldehyde-3-phosphate Dehydrogenase Enhances Transcriptional Activity of Androgen Receptor in Prostate Cancer Cells
J. Biol. Chem., August 3, 2007; 282(31): 22651 - 22661.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
V. J. Armstrong, M. Muzylak, A. Sunters, G. Zaman, L. K. Saxon, J. S. Price, and L. E. Lanyon
Wnt/beta-Catenin Signaling Is a Component of Osteoblastic Bone Cell Early Responses to Load-bearing and Requires Estrogen Receptor {alpha}
J. Biol. Chem., July 13, 2007; 282(28): 20715 - 20727.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
K. J. Bruxvoort, H. M. Charbonneau, T. A. Giambernardi, J. C. Goolsby, C.-N. Qian, C. R. Zylstra, D. R. Robinson, P. Roy-Burman, A. K. Shaw, B. D. Buckner-Berghuis, et al.
Inactivation of Apc in the Mouse Prostate Causes Prostate Carcinoma
Cancer Res., March 15, 2007; 67(6): 2490 - 2496.
[Abstract] [Full Text] [PDF]

Home page
 Endocr Relat CancerHome page
C. J Burd, L. M Morey, and K. E Knudsen
Androgen receptor corepressors and prostate cancer
Endocr. Relat. Cancer, December 1, 2006; 13(4): 979 - 994.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
S. Takayama, I. Rogatsky, L. E. Schwarcz, and B. D. Darimont
The Glucocorticoid Receptor Represses Cyclin D1 by Targeting the Tcf-beta-Catenin Complex
J. Biol. Chem., June 30, 2006; 281(26): 17856 - 17863.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
S.-Y. Chen, G. Wulf, X. Z. Zhou, M. A. Rubin, K. P. Lu, and S. P. Balk
Activation of {beta}-Catenin Signaling in Prostate Cancer by Peptidyl-Prolyl Isomerase Pin1-Mediated Abrogation of the Androgen Receptor-{beta}-Catenin Interaction
Mol. Cell. Biol., February 1, 2006; 26(3): 929 - 939.
[Abstract] [Full Text] [PDF]

Home page
 Endocr. Rev.Home page
D. J. Mulholland, S. Dedhar, G. A. Coetzee, and C. C. Nelson
Interaction of Nuclear Receptors with the Wnt/{beta}-Catenin/Tcf Signaling Axis: Wnt You Like to Know?
Endocr. Rev., December 1, 2005; 26(7): 898 - 915.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
C. Fonte, J. Grenier, A. Trousson, A. Chauchereau, O. Lahuna, E.-E. Baulieu, M. Schumacher, and C. Massaad
Involvement of {beta}-catenin and unusual behavior of CBP and p300 in glucocorticosteroid signaling in Schwann cells
PNAS, October 4, 2005; 102(40): 14260 - 14265.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Endocrinol.Home page
M. Verras and Z. Sun
{beta}-Catenin Is Involved in Insulin-Like Growth Factor 1-Mediated Transactivation of the Androgen Receptor
Mol. Endocrinol., February 1, 2005; 19(2): 391 - 398.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2004 by The Endocrine Society